湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-078 湖南方盛制药股份有限公司 关于2025年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司（以下简称"方盛制药"或"公 司"）于 2025 年 8 月 29 日（星期五）上午 09:00—10:00 以网络 互动方式，通过上证路演中心召开 2025 年半年度业绩说明会， 就公司 2025 年半年度经营业绩情况，以及其他投资者普遍关心 的问题与投资者进行交流与沟通。现将有关情况公告如下： 一、本次说明会召开情况 出席本次网上业绩说明会的公司人员为：董事长兼总经理周 晓莉女士、独立董事袁雄先生、财务总监曹湘琦女士、董事会秘 书何仕先生。 二、投资者提出的主要问题及公司回复情况 公司就投资者在本次说明会上提出的问题进行了回复，相关 问题及回复整理如下： 问题 1、请问公司今年有什么创新上的突破或方向吗？ ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 834 million yuan in H1 2025, a year-on-year decrease of 8.35%, while the net profit attributable to the parent company increased by 23.67% to 169 million yuan [4] - The company maintains a strong focus on innovative traditional Chinese medicine, which is expected to enhance its long-term competitive edge [4] - The forecast for net profit attributable to the parent company for 2025-2027 is 308 million, 378 million, and 457 million yuan respectively, with corresponding EPS of 0.70, 0.86, and 1.04 yuan [4] Financial Performance Summary - In H1 2025, the gross profit margin was 70.30%, a decrease of 2.36 percentage points, while the net profit margin increased by 5.06 percentage points to 19.96% [4] - The sales expense ratio decreased by 8.21 percentage points to 33.58%, while the R&D expense ratio increased by 1.42 percentage points to 8.16% [4] - The company reported a significant increase in revenue from cardiovascular drugs, which reached 276 million yuan, up 16.05% [5] Product Development and Innovation - The company plans to acquire the patent rights for a Class 1 innovative chemical drug, IMM-H024, for 80 million yuan, which is expected to strengthen its innovative drug pipeline [6] - The "Yangxue Qufeng Zhitong Granules" is the company's third innovative traditional Chinese medicine product, which has passed preliminary review for inclusion in the national basic medical insurance directory [6]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) reported a decline in revenue and profitability in its 2025 mid-year report, indicating challenges in its operational performance [1] Financial Performance - The company's total revenue for the period was 834 million yuan, a decrease of 76 million yuan compared to the same period last year, representing a year-on-year decline of 8.35% [1] - The net profit attributable to shareholders was 169 million yuan [1] - The net cash inflow from operating activities was 129 million yuan [1] Financial Ratios - The latest debt-to-asset ratio stood at 43.90%, ranking 45th among disclosed peers [1] - The gross profit margin was 70.30%, down 0.20 percentage points from the previous quarter and down 2.36 percentage points year-on-year [1] - The return on equity (ROE) was reported at 10.33% [1] Earnings and Efficiency Metrics - The diluted earnings per share were 0.39 yuan [1] - The total asset turnover ratio was 0.26 times, a decrease of 0.02 times compared to the same period last year, reflecting an 8.56% year-on-year decline [1] - The inventory turnover ratio was 0.65 times, ranking 47th among disclosed peers, and decreased by 0.06 times year-on-year, representing a decline of 7.83% [1]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 该议案表决情况：6 票同意，0 票反对，0 票弃权，表决通过。 二、关于公司 2025 年半年度利润分配方案的预案 董事会提议：拟以公告实施利润分配的股权登记日当天收盘后的 总股本为基数，向股权登记日在册全体股东每 10 股派发 1.50 元现金 红利（含税），不送红股，不进行资本公积金转增股本。 上述预案在 2024 年年度股东大会授权范围内，公司将在法定时限 第 1页，共 2页 证券代码：603998 证券简称：方盛制药 公告编号：2025-075 湖南方盛制药股份有限公司 第六届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司（以下简称"公司"）第六届董事会 第三次会议于 2025 年 8 月 27 日下午 14:30 在公司办公大楼一楼会议 室（一）以现场与通讯表决相结合的方式召开。公司证券部已于 2025 年 8 月 17 日以电子邮件、微信、电话等方式通知全体董 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-076 截至 2025 年 6 月 30 日，公司母公司报表中期末未分配利润 为人民币 957,659,358.77 元。经董事会决议，公司 2025 年半年 度拟以实施权益分派股权登记日登记的总股本为基数分配利润。 本次利润分配方案如下： 上市公司拟向全体股东每股派发现金红利 0.15 元（含税）。 截至 2025 年 6 月 30 日，公司总股本 439,081,360 股，以此计算 合计拟派发现金红利 65,862,204 元（含税），占公司 2025 年半 年度归属于上市公司股东的净利润比例为 38.92%。 如在本公告披露之日起至实施权益分派股权登记日期间，公 司总股本发生变动，公司拟维持每股分配比例不变，相应调整分 配总额。如后续总股本发生变化，将另行公告具体调整情况。 本次利润分配方案无需提交股东会审议。 湖南方盛制药股份有限公司 关于 2025 年半年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 ...

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) reported a decline in revenue for the first half of the year, while net profit showed significant growth [1] Financial Performance - The company achieved operating revenue of 834.25 million yuan, a year-on-year decrease of 8.35% [1] - The net profit attributable to shareholders of the listed company was 169.24 million yuan, reflecting a year-on-year increase of 23% [1]

[Important Notice](index=2&type=section&id=Important%20Notice) This section provides critical disclaimers and affirmations regarding the semi-annual report's accuracy and the company's operational status. [I. Board of Directors and Senior Management Statement](index=2&type=section&id=I.%20Board%20of%20Directors%20and%20Senior%20Management%20Statement) The Board of Directors and senior management affirm the semi-annual report's truthfulness, accuracy, and completeness, assuming legal responsibility - The Board of Directors and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report[5](index=5&type=chunk) - Company head Zhou Xiaoli, chief accountant Cao Xiangqi, and accounting department head Cao Xiangqi affirm the financial report's truthfulness, accuracy, and completeness[6](index=6&type=chunk) [II. Board Meeting Attendance](index=2&type=section&id=II.%20Board%20Meeting%20Attendance) All company directors attended the Board of Directors meeting - All company directors attended the Board of Directors meeting[5](index=5&type=chunk) [III. Report Audit Status](index=2&type=section&id=III.%20Report%20Audit%20Status) This semi-annual report is unaudited - This semi-annual report is unaudited[5](index=5&type=chunk) [V. Profit Distribution Plan](index=2&type=section&id=V.%20Profit%20Distribution%20Plan) The Board approved a profit distribution plan of **1.50 yuan (tax inclusive) cash dividend per 10 shares** to all registered shareholders, with no bonus shares or capital reserve conversions - The Board approved a **1.50 yuan (tax inclusive) cash dividend per 10 shares** to all registered shareholders based on the total share capital on the equity registration date for profit distribution[6](index=6&type=chunk) - No bonus shares or capital reserve conversions[6](index=6&type=chunk) [VI. Forward-Looking Statements Risk Disclaimer](index=2&type=section&id=VI.%20Forward-Looking%20Statements%20Risk%20Disclaimer) Forward-looking statements regarding future plans and strategies do not constitute a substantial commitment to investors, urging caution on investment risks - Forward-looking statements regarding future plans and development strategies in this report do not constitute a substantial commitment to investors[7](index=7&type=chunk) - Investors are advised to be aware of investment risks[7](index=7&type=chunk) [VII. Controlling Shareholder and Related Party Fund Occupation](index=2&type=section&id=VII.%20Controlling%20Shareholder%20and%20Related%20Party%20Fund%20Occupation) There is no non-operating occupation of funds by controlling shareholders or other related parties - No non-operating occupation of funds by controlling shareholders or other related parties[8](index=8&type=chunk) [VIII. External Guarantees](index=2&type=section&id=VIII.%20External%20Guarantees) The company has not provided external guarantees in violation of prescribed decision-making procedures - No external guarantees were provided in violation of prescribed decision-making procedures[8](index=8&type=chunk) [IX. Directors' Assurance of Report Authenticity](index=2&type=section&id=IX.%20Directors'%20Assurance%20of%20Report%20Authenticity) No more than half of the directors are unable to guarantee the truthfulness, accuracy, and completeness of the semi-annual report - No more than half of the directors are unable to guarantee the truthfulness, accuracy, and completeness of the company's semi-annual report[8](index=8&type=chunk) [X. Significant Risk Alerts](index=2&type=section&id=X.%20Significant%20Risk%20Alerts) No particularly significant risks substantially affecting operations were identified during the reporting period; detailed risks are in the 'Potential Risks' section of Management Discussion and Analysis - No particularly significant risks substantially affecting the company's operations were identified during the reporting period[8](index=8&type=chunk) - The company has detailed various risks in its operations in this report, see "Potential Risks" in "Section III Management Discussion and Analysis"[8](index=8&type=chunk) [Section I Definitions](index=4&type=section&id=Section%20I%20Definitions) This section provides a glossary of common terms used throughout the report, including company and subsidiary names, industry jargon, and regulatory bodies [Definitions of Common Terms](index=4&type=section&id=Definitions%20of%20Common%20Terms) This section defines common terms, including company and subsidiary names, industry jargon (e.g., GMP, OTC, innovative traditional Chinese medicine), and regulatory bodies, providing a basis for understanding the report - Glossary of common terms, including names of subsidiaries such as the Company, Lühe Pharmaceutical, Fangsheng Jianmeng, and Fuya Bio[14](index=14&type=chunk) - Explanation of industry terms such as GMP (Good Manufacturing Practice), OTC (Over-the-Counter drugs), and innovative traditional Chinese medicine[15](index=15&type=chunk) - Lists regulatory bodies including MIIT, National Healthcare Security Administration, National Health Commission, CSRC, SSE, and NMPA[15](index=15&type=chunk) [Section II Company Profile and Key Financial Indicators](index=6&type=section&id=Section%20II%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section provides an overview of the company's basic information and presents its key financial performance metrics [I. Company Information](index=6&type=section&id=I.%20Company%20Information) This section provides basic registration information, including the company's Chinese name, abbreviation, foreign name, and legal representative - The company's Chinese name is Hunan Fangsheng Pharmaceutical Co., Ltd., abbreviated as Fangsheng Pharmaceutical[17](index=17&type=chunk) - The company's legal representative is Zhou Xiaoli[17](index=17&type=chunk) [II. Contact Persons and Contact Information](index=6&type=section&id=II.%20Contact%20Persons%20and%20Contact%20Information) This section lists the names, contact addresses, phone numbers, fax numbers, and email addresses of the Board Secretary and Securities Affairs Representative - The Board Secretary is He Shi, and the Securities Affairs Representative is Wang Chaoxia[18](index=18&type=chunk) - Contact phone number is 0731-88997135, and email addresses are heshi001@fangsheng.com.cn and wangchaoxia@fangsheng.com.cn respectively[18](index=18&type=chunk) [III. Brief Introduction to Changes in Basic Information](index=6&type=section&id=III.%20Brief%20Introduction%20to%20Changes%20in%20Basic%20Information) This section details the company's registered and office addresses, noting no changes during the reporting period - The company's registered address is No. 789 Lusong Road, High-tech Zone, Changsha, and its office address is No. 299 Jiayun Road, National High-tech Industrial Development Zone, Changsha[19](index=19&type=chunk) - No changes to the company's registered or office addresses during the reporting period[19](index=19&type=chunk) [IV. Brief Introduction to Changes in Information Disclosure and Document Storage Locations](index=6&type=section&id=IV.%20Brief%20Introduction%20to%20Changes%20in%20Information%20Disclosure%20and%20Document%20Storage%20Locations) This section discloses the designated newspapers for information disclosure, the website address for the semi-annual report, and the report's storage location, with no changes during the reporting period - The company's designated information disclosure newspapers are China Securities Journal, Shanghai Securities News, Securities Times, and Securities Daily[20](index=20&type=chunk) - The website address for the semi-annual report is www.sse.com.cn[20](index=20&type=chunk) - The company's semi-annual report is available at No. 299 Jiayun Road, National High-tech Industrial Development Zone, Changsha, with no changes during the reporting period[20](index=20&type=chunk) [V. Company Stock Overview](index=6&type=section&id=V.%20Company%20Stock%20Overview) This section provides the company's stock type, listing exchange, stock abbreviation, and stock code - The company's stock type is A-shares, listed on the Shanghai Stock Exchange[21](index=21&type=chunk) - Stock abbreviation is Fangsheng Pharmaceutical, stock code is 603998[21](index=21&type=chunk) [VII. Company Key Accounting Data and Financial Indicators](index=6&type=section&id=VII.%20Company%20Key%20Accounting%20Data%20and%20Financial%20Indicators) This section details key accounting data and financial indicators for H1 2025 versus prior year, explaining revenue decline alongside improved profitability H1 2025 Key Accounting Data vs. Prior Period | Indicator | Current Period (Jan-Jun) | Prior Period | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 834.25 million yuan | 910.25 million yuan | -8.35 | | Total Profit | 186.49 million yuan | 155.20 million yuan | 20.16 | | Net Profit Attributable to Shareholders | 169.24 million yuan | 136.84 million yuan | 23.67 | | Net Profit Attributable to Shareholders After Non-Recurring Gains/Losses | 141.47 million yuan | 110.71 million yuan | 27.79 | | Net Cash Flow from Operating Activities | 129.49 million yuan | 66.34 million yuan | 95.19 | | Net Assets Attributable to Shareholders (Period-End) | 1.639 billion yuan | 1.511 billion yuan | 8.43 | | Total Assets (Period-End) | 3.057 billion yuan | 3.227 billion yuan | -5.29 | H1 2025 Key Financial Indicators vs. Prior Period | Indicator | Current Period (Jan-Jun) | Prior Period | Change (%) | | :--- | :--- | :--- | :--- | | Basic EPS (yuan/share) | 0.39 | 0.32 | 21.88 | | Diluted EPS (yuan/share) | 0.

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 说明： 1、主营业务分行业情况中，"医疗业务及其他"为子公司永州方盛天鸿肿瘤医院 有限公司医疗服务业务收入、子公司重庆筱熊猫药业股份有限公司和湖南方盛锐新药业 有限公司（分别于 2024 年 4 月、6 月后不再纳入合并范围）医药销售业务收入、子公司 广东暨大基因药物工程研究中心有限公司的医药技术服务收入、子公司云南芙雅生物科 技有限公司植物提取产品收入； 证券代码：603998 证券简称：方盛制药 公告编号：2025-077 湖南方盛制药股份有限公司 2025年半年度经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司行业信息披露指引第六号——医药制造》的 相关规定，湖南方盛制药股份有限公司（以下简称"公司"）现 将 2025 年上半年度主要经营数据披露如下（单位：元，人民币）： | | | ...

Group 1 - The core viewpoint of the news is that Fangsheng Pharmaceutical (603998) has shown a mixed performance in its latest financial results, with a decrease in total revenue but an increase in net profit [1] - As of August 25, 2025, Fangsheng Pharmaceutical's stock closed at 12.63 yuan, up 3.87%, with a trading volume of 637,500 hands and a transaction amount of 799 million yuan [1] - The company's latest quarterly report indicates total revenue of 418 million yuan, a year-on-year decrease of 4.62%, while net profit attributable to shareholders reached 88.26 million yuan, a year-on-year increase of 25.74% [1] Group 2 - The company has a liquidity ratio of 0.829 and a quick ratio of 0.511, with a debt-to-asset ratio of 44.14% [1] - Fangsheng Pharmaceutical has made investments in 42 companies and participated in 4,804 bidding projects, indicating active engagement in the market [2] - The company holds 115 trademark registrations and 62 patents, along with 169 administrative licenses, showcasing its commitment to intellectual property and regulatory compliance [2]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-074 湖南方盛制药股份有限公司 关于公司参与投资设立的并购基金对外出售投资 项目部分股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示：同系方盛投资的湖南珂信已将其持有的长沙珂信 51%的股权转 让至盈康生命，且盈康生命已支付相关转让价款。湖南珂信对回购价款及各期支付金额 进行调整，调整后，同系方盛预计将获得回购款 15,460.06 万元，湖南珂信将支付至同 系方盛的第一期回购款为 7,764.54 万元。2025 年 8 月 25 日，公司收到同系方盛向公司 分配项目处置款 7,764.54 万元； 风险提示：截至本公告披露日，公司对同系方盛的实缴出资尚有 2,085.46 万元 未收回。湖南珂信将持有的长沙珂信 51%的股权转让至盈康生命的交易已完成，但湖南 珂信能否完成业绩承诺继续向盈康生命转让长沙珂信 29%、20%的股权 ...